newsflash week 05.2025

Welcome back to this week's newsflash

  1. We've added a new wiki article discussing the effects of popular diets on ulcerative colitis. To help spread this info, automod will be posting links to the wiki in relevant threads. Feel free to link to the wiki page yourself whenever you see a discussion about diet and UC! Do you want to know more?
  2. This is an article about bowel cancer risk prediction in people with inflammatory bowel disease. It discusses the development of a new algorithm that can predict the risk of future bowel cancer based on the exact pattern of DNA altered in pre-cancerous cells. The algorithm can predict which people with IBD who develop pre-cancerous cells will go on to develop bowel cancer within 5 years with greater than 90% accuracy. Do you want to know more?
  3. This is an article about the Gut Cell Atlas, a map of the human gut that catalogs data from over 1.6 million cells. The Gut Cell Atlas is a visual representation of the interactions between genes and proteins found in different types of gut cells. It also discusses gut metaplastic cells, which are normally found in the stomach and are involved in helping the lining of the stomach heal from inflammation. In people with Crohn’s disease and celiac disease, these cells are found in the small intestines, where they don’t normally belong. Do you want to know more?
  4. This is an article about predicting bowel cancer risk in people with IBD. It discusses a new DNA testing method that can identify people with IBD who are at high risk of developing bowel cancer. The test is more than 90% accurate at predicting which pre-cancerous cells will develop into bowel cancer within 5 years. The next step is to develop the technology into a test that can be used in hospitals. The test should mean fewer people with IBD have to face the difficult choice between surgery and regular monitoring with colonoscopies. Do you want to know more?
  5. This article discusses diet trends for 2025 and IBD. It discusses adding protein to more foods, electrolyte-enhanced waters, and a rise in fermented foods. Some of these new trends are not compatible with IBD. Protein needs are higher for people with IBD. Drinks with added sugar or sugar substitutes can promote diarrhea. Do you want to know more?
  6. This is an article about OSE Immunotherapeutics’s anti-IL-7R. It discusses their drug Lusvertikimab and its effect on ulcerative colitis. The drug is in clinical development. The article also details the company’s plan to present three abstracts at the 20th Congress of ECCO. These abstracts will be presented in Oral Presentation, Digital Oral Presentation, and Poster Presentation. Do you want to know more?
  7. This is an article about mesalazine-induced acute pancreatitis. It discusses the link between mesalazine and acute pancreatitis. This study aims to explore the characteristics of mesalazine-induced AP. Mesalazine-induced AP is a rare but significant adverse reaction. The reaction can recur upon rechallenge. Do you want to know more?
  8. New research reveals differences in how South Asian and white patients experience inflammatory bowel disease. The analysis of nearly 40,000 patients highlights variations in age, type, and severity of the disease between these ethnic groups. Do you want to know more?
  9. This is an article about the efficacy and safety of biosimilars in pediatric inflammatory bowel disease. It discusses the use of biosimilars for infliximab and adalimumab in pediatric patients with IBD. The study found no increased risk of treatment failure or all-cause hospitalization rates between biosimilars and originators. Biosimilars are not linked to an increased risk of treatment failure among pediatric patients with IBD. The study highlights the importance of pediatric-specific studies due to the increasing diagnosis rates in children. Do you want to know more?
  10. This is an article about infliximab clearance in patients with ulcerative colitis. It discusses the effects of a standard infliximab regimen on patients with acute severe ulcerative colitis (ASUC). The authors found that infliximab clearance is substantially increased among hospitalised patients with severe UC, resulting in underexposure in the majority of patients treated with a standard dosing regimen. An intensified regimen should be considered preferably supported by therapeutic drug monitoring and PK modelling. Do you want to know more?
  11. This is an article about the Ulcerative Colitis Global Market. It discusses the market size, growth rate, key drivers and trends. The market is expected to grow from $7.39 billion in 2024 to $7.89 billion in 2025, signifying a strong growth with a CAGR of 6.7%. Do you want to know more?
  12. This is an article about wearable devices predicting IBD. It discusses using information from everyday wrist-worn devices to predict flare-ups. The devices already track heart rate, heart rate variability, steps, and pulse oximetry. This information can exhibit significant changes far in advance of IBD flare-ups. With such advance notice, it will be possible for people with IBD and their physicians to adjust medications to blunt the upcoming flares before it arrives. Do you want to know more?
  13. Important points from this article are that researchers may have found a cause of ulcerative colitis and that a potential treatment is being tested. The potential cause is a lack of a certain family of bacteria. The potential treatment is supplementation with secondary bile acids. Do you want to know more?

That's it for this week. Stay healthy!